NCT07469709Recruiting
A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
A Platform for Assessing Personal Risk of Developing or Recurring of Cancer: Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring of Subclinical Recurrences With Therapeutic Impact
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase. The PRO-ACTIVE study includes the following activities: * WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors * WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences * WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors * WP4: Study of the tumor microenvironment for recurrence prediction
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 850 (estimated)
- First submitted
- 3 Mar 2026
- Start date
- Feb 2024
- Primary completion date
- May 2027
- Lead sponsor
- Fondazione del Piemonte per l'Oncologia
- Diseases
- Melanoma, Lung cancer, Colorectal cancer, Ovarian cancer
- NCT number
- NCT07469709
What you commit to
- Study type: Observational
- Planned participants: 850
- From Feb 2024 to the primary completion date, May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \<18 years;
Other
- Unwillingness or inability to give informed consent
Who the study is looking for
- Age \>18 years;
- Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer;
- Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion;
- Patients with ovarian carcinomas;
- Patients with metastatic melanoma;
- Patients with stage IIB and IIIA non-small cell lung cancer.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione del Piemonte per l'Oncologia IRCCS Candiolo Coordinator of this site? Confirm its status | Candiolo | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.